|
|
|
| home > white papers > Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models - DrugDev |
|
|
 WHITE PAPERS |
|
DrugDev
|
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
|
|
For the last 20 years, pharmaceutical companies have turned to a variety
of clinical outsourcing solutions to reduce costs and improve
timelines, enabling them to focus on their core value of research and
development. In today’s tightly competitive market, companies are
constantly striving for ways to further cut costs and reduce study
startup cycle times, while maintaining quality.
One of the key
cost factors in global R&D spending, estimated at around $102
billion per Kalorama market research, is the cost of conducting clinical
trials. CRO’s, which account for about 30% of the total R&D
spending, have risen to the challenge of the clinical, technical and
administrative management of these trials. But some pharmaceutical
companies question how much control to relinquish to vendor partners,
especially in the legal arena, due to potential ramifications.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Blood Tests May Prevent Relapse in Breast Cancer Patients
The Royal Marsden NHS Foundation Trust is leading an international
research collaboration to offer blood tests that can identify risk of
relapse in breast cancer patients. The trial will assess whether
personalised blood tests can show which patients will relapse, years
before it’s shown on a scan - treatment can then be altered to try and
prevent relapse from happening. There are currently no effective tests
to establish which patients are at risk of relapse after previous
treatment for breast cancer.
More info >> |
|
 |
White Papers |
 |
|
Financial implications of off-site visits in clinical research, perception versus reality
Illingworth Research
The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off -site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off -site nursing more expensive than the traditional site model?
More info >> |
|
|
|
